Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp in acute vulvovaginal candidiasis
NCT03987620Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of ibrexafungerp in vulvovaginal candidiasis (VVC), sponsored by SCYNEXIS, Inc.. Started Jun 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT03987620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987620.